{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:13:24Z","timestamp":1777864404886,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd011373","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T00:00:00Z","timestamp":1509926400000}}],"reference-count":212,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011373.pub2","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T02:21:04Z","timestamp":1509934864000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease"],"prefix":"10.1002","volume":"2017","author":[{"given":"Miho","family":"Kimachi","sequence":"first","affiliation":[{"name":"School of Public Health in the Graduate School of Medicine, Kyoto University; Department of Healthcare Epidemiology; Yoshida Konoe-cho, Sakyo-ku Kyoto Kyoto Japan 606-8501"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshi A","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine\/School of Public Health; Department of Health Promotion and Human Behavior; Yoshida Konoe-cho, Sakyo-ku, Kyoto Japan 606-8501"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimihiko","family":"Kimachi","sequence":"additional","affiliation":[{"name":"School of Public Health in the Graduate School of Medicine, Kyoto University; Department of Healthcare Epidemiology; Yoshida Konoe-cho, Sakyo-ku Kyoto Kyoto Japan 606-8501"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihito","family":"Goto","sequence":"additional","affiliation":[{"name":"Kyoto University School of Public Health; Department of Health Informatics; Yoshida Konoecho, Sakyo-ku Kyoto Japan 606-8501"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Fukuma","sequence":"additional","affiliation":[{"name":"School of Public Health in the Graduate School of Medicine, Kyoto University; Department of Healthcare Epidemiology; Yoshida Konoe-cho, Sakyo-ku Kyoto Kyoto Japan 606-8501"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichi","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"School of Public Health in the Graduate School of Medicine, Kyoto University; Department of Healthcare Epidemiology; Yoshida Konoe-cho, Sakyo-ku Kyoto Kyoto Japan 606-8501"},{"name":"Fukushima Medical University; Center for Innovative Research for Communities and Clinical Excellence; Fukushima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,11,6]]},"reference":[{"issue":"31","key":"10.1002\/14651858.CD011373.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/eurheartj\/eht135","article-title":"Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial","volume":"34","author":"Al-Khatib","year":"2013","journal-title":"European Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD011373.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ahj.2013.05.025","article-title":"Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial","volume":"166","author":"Alexander","year":"2013","journal-title":"American Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD011373.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander","year":"2014","journal-title":"European Heart Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0004|cit4","first-page":"AWP147","article-title":"Apixaban versus warfarin in patients with atrial fibrillation: patient characteristics of the Latin America cohort from a multinational clinical trial [abstract]","volume":"46","author":"Avezum","year":"2015","journal-title":"Stroke"},{"issue":"8","key":"10.1002\/14651858.CD011373.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","article-title":"Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial","volume":"132","author":"Avezum","year":"2015","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/eurheartj\/eht310.4384","article-title":"Apixaban versus warfarin in patients with atrial fibrillation and valvular heart disease: findings from the ARISTOTLE trial [abstract]","volume":"34","author":"Avezum","year":"2013","journal-title":"European Heart Journal"},{"issue":"21 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0007|cit7","article-title":"Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial [abstract no: 13026]","volume":"126","author":"Bahit","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD011373.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijcard.2013.10.062","article-title":"Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial","volume":"170","author":"Bahit","year":"2013","journal-title":"International Journal of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD011373.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/jth.12638","article-title":"D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial","volume":"12","author":"Christersson","year":"2014","journal-title":"Journal of Thrombosis & Haemostasis"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ahj.2016.01.005","article-title":"History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial","volume":"175","author":"Caterina","year":"2016","journal-title":"American Heart Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011373.pub2-BIB0011|cit11","first-page":"47","article-title":"Apixaban compared with warfarin in patients with atrial fibrillation and prior stroke or TIA: a subgroup analysis of the ARISTOTLE trial [abstract]","volume":"33","author":"Diener","year":"2012","journal-title":"Cerebrovascular Diseases"},{"issue":"28","key":"10.1002\/14651858.CD011373.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/eurheartj\/ehu006","article-title":"Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation","volume":"35","author":"Dorian","year":"2014","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijcard.2015.09.062","article-title":"Chronic obstructive pulmonary disease in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"202","author":"Durheim","year":"2016","journal-title":"International Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD011373.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1474-4422(12)70092-3","article-title":"Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.[Erratum appears in Lancet Neurol. 2012 Dec;11(12):1021]","volume":"11","author":"Easton","year":"2012","journal-title":"Lancet Neurology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S334","DOI":"10.1016\/j.cjca.2011.07.611","article-title":"Efficacy and safety of apixaban compared to warfarin for prevention of stroke and systemic embolism in 18,201 patients with atrial fibrillation: Primary results of the ARISTOTLE trial [abstract]","volume":"27","author":"Ezekowitz","year":"2011","journal-title":"Canadian Journal of Cardiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0016|cit16","first-page":"686","article-title":"Apixaban and warfarin are associated with a low risk of stroke following cardioversion for atrial fibrillation: results from the ARISTOTLE Trial [abstract no: 4048]","volume":"33","author":"Flaker","year":"2012","journal-title":"European Heart Journal"},{"issue":"11","key":"10.1002\/14651858.CD011373.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2013.09.062","article-title":"Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation)","volume":"63","author":"Flaker","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"15","key":"10.1002\/14651858.CD011373.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.jacc.2014.07.967","article-title":"Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"64","author":"Flaker","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"E317","DOI":"10.1016\/S0735-1097(13)60317-4","article-title":"Apixaban is efficacious and safe in patients with atrial fibrillation using concomitant amiodarone: an analysis from the ARISTOTLE trial [abstract]","volume":"61","author":"Flaker","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"21 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0020|cit20","article-title":"Apixaban versus warfarin in patients with atrial fibrillation in relation to prior warfarin use: Insights from the ARISTOTLE trial [abstract no: 14771]","volume":"126","author":"Garcia","year":"2012","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD011373.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ahj.2013.05.016","article-title":"Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial","volume":"166","author":"Garcia","year":"2013","journal-title":"American Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD011373.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ahj.2014.06.005","article-title":"Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial","volume":"168","author":"Goto","year":"2014","journal-title":"American Heart Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0023|cit23","first-page":"685","article-title":"Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial [abstract no: 4045]","volume":"33","author":"Granger","year":"2012","journal-title":"European Heart Journal"},{"issue":"11","key":"10.1002\/14651858.CD011373.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"28","key":"10.1002\/14651858.CD011373.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial","volume":"35","author":"Halvorsen","year":"2014","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/eht307.P536","article-title":"Risk of events in the 30 days following a major bleed with Apixaban or Warfarin - experiences from the ARISTOTLE trial [abstract]","volume":"34","author":"Held","year":"2013","journal-title":"European Heart Journal"},{"issue":"20","key":"10.1002\/14651858.CD011373.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/eurheartj\/ehu463","article-title":"Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial","volume":"36","author":"Held","year":"2015","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD011373.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1161\/CIRCULATIONAHA.113.006286","article-title":"High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"129","author":"Hijazi","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD011373.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1373\/clinchem.2014.226936","article-title":"Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy","volume":"61","author":"Hijazi","year":"2015","journal-title":"Clinical Chemistry"},{"issue":"1","key":"10.1002\/14651858.CD011373.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jacc.2013.07.093","article-title":"High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin","volume":"63","author":"Hijazi","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"22","key":"10.1002\/14651858.CD011373.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.jacc.2012.11.082","article-title":"N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation)","volume":"61","author":"Hijazi","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"22","key":"10.1002\/14651858.CD011373.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","article-title":"Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"33","author":"Hohnloser","year":"2012","journal-title":"European Heart Journal"},{"issue":"9855","key":"10.1002\/14651858.CD011373.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(12)60986-6","article-title":"Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.[Erratum appears in Lancet. 2013 Jan 19;381(9862):204]","volume":"380","author":"Lopes","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD011373.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.[Erratum appears in Am Heart J. 2010 Jun;159(6):1162]","volume":"159","author":"Lopes","year":"2010","journal-title":"American Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD011373.pub2-BIB0035|cit35","first-page":"451","article-title":"Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"6","author":"McMurray","year":"2013","journal-title":"Circulation: Heart Failure"},{"issue":"8","key":"10.1002\/14651858.CD011373.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1253\/circj.CJ-10-1183","article-title":"Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation","volume":"75","author":"Ogawa","year":"2011","journal-title":"Circulation Journal"},{"issue":"12","key":"10.1002\/14651858.CD011373.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"e002015","DOI":"10.1161\/JAHA.115.002015","article-title":"Blood pressure control and risk of stroke or systemic embolism inpatients with atrial fibrillation: results from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial","volume":"4","author":"Rao","year":"2015","journal-title":"Journal of the American Heart Association"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0038|cit38","first-page":"1068","article-title":"Digoxin use is associated with higher mortality among patients with atrial fibrillation with and without heart failure: insights from the ARISTOTLE trial [abstract]","volume":"36","author":"Rordorf","year":"2015","journal-title":"European Heart Journal"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"A284","DOI":"10.1016\/S0735-1097(15)60284-4","article-title":"Body mass index and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the ARISTOTLE (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) trial [abstract]","volume":"65","author":"Sandhu","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"issue":"38","key":"10.1002\/14651858.CD011373.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1093\/eurheartj\/ehw124","article-title":"The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial","volume":"37","author":"Sandhu","year":"2016","journal-title":"European Heart Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0041|cit41","first-page":"51","article-title":"Increased levels of D-dimer identify patients with atrial fibrillation at high risk for bleeding an ARISTOTLE substudy [abstract no: P553]","volume":"33","author":"Siegbahn","year":"2012","journal-title":"European Heart Journal"},{"issue":"46","key":"10.1002\/14651858.CD011373.pub2-BIB0042|cit42","first-page":"3268","article-title":"Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial","volume":"36","author":"Vinereanu","year":"2015","journal-title":"European Heart Journal"},{"issue":"22","key":"10.1002\/14651858.CD011373.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1161\/CIRCULATIONAHA.112.142158","article-title":"Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation","volume":"127","author":"Wallentin","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD011373.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0045|cit45","first-page":"E964","article-title":"Cardiac structure and function and CHADS2 risk score in patients with atrial fibrillation: the effective anticoagulation with factor Xa next generation in afthrombolysis in myocardial infarction 48 (ENGAGE AF -TIMI 48) echocardiographic study [abstract]","volume":"61","author":"Deepak","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"A2092","DOI":"10.1016\/S0735-1097(15)62092-7","article-title":"Perioperative adverse outcomes in patients with atrial fibrillation taking edoxaban or warfarin: analysis of the ENGAGE AF-TIMI 48 trial [abstract]","volume":"65","author":"Douketis","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ahj.2015.11.004","article-title":"Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: an analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial","volume":"172","author":"Eisen","year":"2016","journal-title":"American Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD011373.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ahj.2015.06.020","article-title":"Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial","volume":"170","author":"Geller","year":"2015","journal-title":"American Heart Journal"},{"issue":"24","key":"10.1002\/14651858.CD011373.pub2-BIB0049|cit49","first-page":"2711","article-title":"ENGAGE AF-TIMI 48 primary results [abstract]","volume":"128","author":"Giugliano","year":"2013","journal-title":"Circulation"},{"issue":"22","key":"10.1002\/14651858.CD011373.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD011373.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1161\/STROKEAHA.114.006025","article-title":"Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48","volume":"45","author":"Giugliano","year":"2014","journal-title":"Stroke"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0052|cit52","first-page":"867","article-title":"Reduction in bleeding with edoxaban vs warfarin linked to lower all-cause mortality in 21,105 patients randomized in the ENGAGE AF-TIMI 48 trial [abstract]","volume":"35","author":"Giugliano","year":"2014","journal-title":"European Heart Journal"},{"issue":"8","key":"10.1002\/14651858.CD011373.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"850-7, e2","DOI":"10.1016\/j.amjmed.2016.02.028","article-title":"Mortality in patients with atrial fibrillation randomized to edoxaban or warfarin: Insights from the ENGAGE AF-TIMI 48 Trial","volume":"129","author":"Giugliano","year":"2016","journal-title":"American Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0054|cit54","first-page":"1117","article-title":"The prognostic significance of cardiac structure and function in atrial fibrillation: the ENGAGE AF-TIMI 48 Echocardiographic Substudy [abstract]","volume":"35","author":"Gupta","year":"2014","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD011373.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.echo.2016.03.004","article-title":"The prognostic significance of cardiac structure and function in atrial fibrillation: The ENGAGE AF-TIMI 48 echocardiographic substudy","volume":"29","author":"Gupta","year":"2016","journal-title":"Journal of the American Society of Echocardiography"},{"issue":"22","key":"10.1002\/14651858.CD011373.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/eurheartj\/eht500","article-title":"Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48","volume":"35","author":"Gupta","year":"2014","journal-title":"European Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD011373.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"e003432","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 Trial","volume":"5","author":"Kato","year":"2016","journal-title":"Journal of the American Heart Association"},{"issue":"9","key":"10.1002\/14651858.CD011373.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s40262-016-0378-3","article-title":"Population pharmacokinetics of edoxaban in patients with non-valvular atrial fibrillation in the ENGAGE AF-TIMI 48 Study, a phase III clinical trial","volume":"55","author":"Krekels","year":"2016","journal-title":"Clinical Pharmacokinetics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0059|cit59","first-page":"A314","article-title":"Impact of spontaneous bleeding events on health state utility in patients with atrial fibrillation: Results from the ENGAGE AF-TIMI 48 trial [abstract no: 314]","volume":"7","author":"Magnuson","year":"2014","journal-title":"Circulation"},{"issue":"9984","key":"10.1002\/14651858.CD011373.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(14)61994-2","article-title":"Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Mega","year":"2015","journal-title":"Lancet"},{"issue":"12 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"A329","DOI":"10.1016\/S0735-1097(14)60329-6","article-title":"Relationship between dose, anti-factor Xa activity, and outcomes in patients randomized to edoxaban in the ENGAGE AF-TIMI 48 trial [abstract]","volume":"63","author":"Ruff","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD011373.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","article-title":"Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor Xa next GEneration in Atrial Fibrillation- Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)","volume":"160","author":"Ruff","year":"2010","journal-title":"American Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD011373.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jacc.2014.05.028","article-title":"Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial","volume":"64","author":"Ruff","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"9984","key":"10.1002\/14651858.CD011373.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Ruff","year":"2015","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0065|cit65","first-page":"440","article-title":"Cardiovascular biomarker score and clinical outcomes in patients with atrial fibrillation enrolled in the ENGAGE AF-TIMI 48 trial [abstract no: P2481]","volume":"35","author":"Ruff","year":"2014","journal-title":"European Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD011373.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1160\/TH11-08-0566","article-title":"Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation","volume":"107","author":"Salazar","year":"2012","journal-title":"Thrombosis & Haemostasis"},{"issue":"12","key":"10.1002\/14651858.CD011373.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1253\/circj.CJ-15-0574","article-title":"Effects of regional differences in Asia on efficacy and safety of edoxaban compared with warfarin: insights from the ENGAGE AF-TIMI 48 trial","volume":"79","author":"Shimada","year":"2015","journal-title":"Circulation Journal"},{"issue":"33","key":"10.1002\/14651858.CD011373.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1093\/eurheartj\/ehv201","article-title":"Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial","volume":"36","author":"Steffel","year":"2015","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD011373.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"e002587","DOI":"10.1161\/JAHA.115.002587","article-title":"Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI48 Trial","volume":"5","author":"Xu","year":"2016","journal-title":"Journal of the American Heart Association"},{"issue":"4","key":"10.1002\/14651858.CD011373.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1253\/circj.CJ-15-1082","article-title":"Edoxaban vs. warfarin in East Asian patients with atrial fibrillation- an ENGAGE AF-TIMI 48 subanalysis","volume":"80","author":"Yamashita","year":"2016","journal-title":"Circulation Journal"},{"issue":"7","key":"10.1002\/14651858.CD011373.pub2-BIB0081|cit71","first-page":"957","article-title":"Safety\/efficacy of rivaroxaban for prevention of stroke in Japanese atrial fibrillation patients - Sub-analysis of renal impairment in J-ROCKET AF [abstract]","volume":"33","year":"2012","journal-title":"Therapeutic Research"},{"issue":"6","key":"10.1002\/14651858.CD011373.pub2-BIB0071|cit72","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1160\/TH12-05-0310","article-title":"Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor","volume":"108","author":"Chan","year":"2012","journal-title":"Thrombosis & Haemostasis"},{"issue":"10","key":"10.1002\/14651858.CD011373.pub2-BIB0072|cit73","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1253\/circj.CJ-13-0726","article-title":"The J-ROCKET AF study: A matter of ethnicity or a matter of weight?","volume":"77","author":"Delgado-Fernandez","year":"2013","journal-title":"Circulation Journal"},{"issue":"10","key":"10.1002\/14651858.CD011373.pub2-BIB0073|cit74","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1253\/circj.CJ-13-0879","article-title":"The J-ROCKET AF study: A matter of ethnicity or a matter of weight?","volume":"77","author":"Hori","year":"2013","journal-title":"Circulation Journal"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0074|cit75","first-page":"20","article-title":"J-ROCKET AF: The safety and efficacy of rivaroxaban for prevention of stroke in Japanese patients with non-valvular atrial fibrillation [abstract]","volume":"9","author":"Hori","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"10.1002\/14651858.CD011373.pub2-BIB0075|cit76","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.07.021","article-title":"Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial","volume":"23","author":"Hori","year":"2014","journal-title":"Journal of Stroke & Cerebrovascular Diseases"},{"issue":"6","key":"10.1002\/14651858.CD011373.pub2-BIB0076|cit77","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1253\/circj.CJ-13-1324","article-title":"Rivaroxaban vs. Warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age","volume":"78","author":"Hori","year":"2014","journal-title":"Circulation Journal"},{"issue":"9","key":"10.1002\/14651858.CD011373.pub2-BIB0077|cit78","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circulation Journal"},{"issue":"3","key":"10.1002\/14651858.CD011373.pub2-BIB0078|cit79","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1253\/circj.CJ-12-0899","article-title":"Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment","volume":"77","author":"Hori","year":"2013","journal-title":"Circulation Journal"},{"issue":"4","key":"10.1002\/14651858.CD011373.pub2-BIB0079|cit80","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2133\/dmpk.DMPK-12-RG-109","article-title":"Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients","volume":"28","author":"Kaneko","year":"2013","journal-title":"Drug Metabolism & Pharmacokinetics"},{"issue":"5","key":"10.1002\/14651858.CD011373.pub2-BIB0080|cit81","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/hr.2014.1","article-title":"Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: A subgroup analysis of the J-ROCKET AF trial","volume":"37","author":"Matsumoto","year":"2014","journal-title":"Hypertension Research - Clinical & Experimental"},{"issue":"8","key":"10.1002\/14651858.CD011373.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.12.010","article-title":"Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: A subgroup analysis of J-ROCKET AF","volume":"22","author":"Tanahashi","year":"2013","journal-title":"Journal of Stroke & Cerebrovascular Diseases"},{"issue":"1","key":"10.1002\/14651858.CD011373.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2133\/dmpk.DMPK-12-RG-034","article-title":"Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation","volume":"28","author":"Tanigawa","year":"2013","journal-title":"Drug Metabolism & Pharmacokinetics"},{"issue":"5","key":"10.1002\/14651858.CD011373.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.10.001","article-title":"Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF","volume":"23","author":"Uchiyama","year":"2014","journal-title":"Journal of Stroke & Cerebrovascular Diseases"},{"issue":"5","key":"10.1002\/14651858.CD011373.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.10.001","article-title":"Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF","volume":"23","author":"Uchiyama","year":"2014","journal-title":"Journal of Stroke & Cerebrovascular Diseases"},{"issue":"23","key":"10.1002\/14651858.CD011373.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jacc.2015.03.577","article-title":"Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY Trial","volume":"65","author":"Bohm","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD011373.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cgh.2012.10.021","article-title":"Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial","volume":"11","author":"Bytzer","year":"2013","journal-title":"Clinical Gastroenterology & Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD011373.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation.[Erratum appears in N Engl J Med. 2010 Nov 4;363(19):1877]","volume":"361","author":"Connolly","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011373.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"issue":"12","key":"10.1002\/14651858.CD011373.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial.[Erratum appears in Lancet Neurol. 2011 Jan;10(1):27]","volume":"9","author":"Diener","year":"2010","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1002\/14651858.CD011373.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1160\/TH14-04-0305","article-title":"Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial","volume":"113","author":"Douketis","year":"2015","journal-title":"Thrombosis & Haemostasis"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2016.01.004","article-title":"Urgent surgery or procedures in patients taking dabigatran or warfarin: analysis of perioperative outcomes from the RE-LY trial","volume":"139","author":"Douketis","year":"2016","journal-title":"Thrombosis Research"},{"issue":"21","key":"10.1002\/14651858.CD011373.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD011373.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"805-10, 810.e1-","DOI":"10.1016\/j.ahj.2009.02.005","article-title":"Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran","volume":"157","author":"Ezekowitz","year":"2009","journal-title":"American Heart Journal"},{"issue":"22","key":"10.1002\/14651858.CD011373.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1161\/CIRCULATIONAHA.110.973735","article-title":"Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation","volume":"122","author":"Ezekowitz","year":"2010","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD011373.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.111.090464","article-title":"Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.[Erratum appears in Circulation. 2012 Sep 4;126(10):e160 Note: Heidbuchle, Hein [corrected to Heidbuchel, Hein]]","volume":"126","author":"Healey","year":"2012","journal-title":"Circulation"},{"issue":"9","key":"10.1002\/14651858.CD011373.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.113.003628","article-title":"Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis","volume":"129","author":"Hijazi","year":"2014","journal-title":"Circulation"},{"issue":"13","key":"10.1002\/14651858.CD011373.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1161\/CIRCULATIONAHA.111.038729","article-title":"Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy","volume":"125","author":"Hijazi","year":"2012","journal-title":"Circulation"},{"issue":"15","key":"10.1002\/14651858.CD011373.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1136\/heartjnl-2013-304872","article-title":"Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy","volume":"100","author":"Hijazi","year":"2014","journal-title":"Heart"},{"issue":"5","key":"10.1002\/14651858.CD011373.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1161\/CIRCULATIONAHA.111.055970","article-title":"Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial","volume":"125","author":"Hohnloser","year":"2012","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD011373.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/STROKEAHA.113.000990","article-title":"Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation","volume":"44","author":"Hori","year":"2013","journal-title":"Stroke"},{"issue":"10","key":"10.1002\/14651858.CD011373.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1253\/circj.CJ-15-0594","article-title":"Efficacy and safety of dabigatran etexilate vs. warfarin in Asian RE-LY patients according to baseline renal function or CHADS2 score","volume":"79","author":"Hori","year":"2015","journal-title":"Circulation Journal"},{"issue":"21","key":"10.1002\/14651858.CD011373.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1161\/CIRCULATIONAHA.113.002332","article-title":"Management and outcomes of major bleeding during treatment with dabigatran or warfarin","volume":"128","author":"Majeed","year":"2013","journal-title":"Circulation"},{"issue":"20","key":"10.1002\/14651858.CD011373.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1161\/CIRCULATIONAHA.112.000491","article-title":"Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study","volume":"128","author":"Marijon","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD011373.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.110.977546","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion","volume":"123","author":"Nagarakanti","year":"2011","journal-title":"Circulation"},{"issue":"10","key":"10.1002\/14651858.CD011373.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-155-10-201111150-00004","article-title":"Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial","volume":"155","author":"Oldgren","year":"2011","journal-title":"Annals of Internal Medicine"},{"issue":"13","key":"10.1002\/14651858.CD011373.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCULATIONAHA.112.001233","article-title":"Genetic determinants of dabigatran plasma levels and their relation to bleeding","volume":"127","author":"Pare","year":"2013","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD011373.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"19","key":"10.1002\/14651858.CD011373.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1161\/CIRCULATIONAHA.112.101808","article-title":"Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial","volume":"126","author":"Spall","year":"2012","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD011373.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.amjcard.2013.10.045","article-title":"Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study)","volume":"113","author":"Verdecchia","year":"2014","journal-title":"American Journal of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD011373.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1161\/CIRCULATIONAHA.112.000708","article-title":"Letter by Apostolakis et al regarding article, \"renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts\"","volume":"128","author":"Apostolakis","year":"2013","journal-title":"Circulation"},{"issue":"12 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"A371","DOI":"10.1016\/S0735-1097(14)60371-5","article-title":"Obesity paradox for stroke in patients with atrial fibrillation treated with rivaroxaban and warfarin in the ROCKET AF trial [abstract]","volume":"63","author":"Balla","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD011373.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ahj.2015.07.006","article-title":"Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)","volume":"170","author":"Bansilal","year":"2015","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0114|cit114","first-page":"1033","article-title":"Patients with native aortic stenosis represent a high-risk subgroup in nonvalvular atrial fibrillation-Results from ROCKET AF [abstract]","volume":"35","author":"Breithardt","year":"2014","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD011373.pub2-BIB0115|cit115","first-page":"A38","article-title":"Comparison of rivaroxaban with warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation: rationale and design of the ROCKET AF study [abstract]","volume":"30","author":"Breithardt","year":"2010","journal-title":"Hamostaseologie"},{"issue":"9","key":"10.1002\/14651858.CD011373.pub2-BIB0116|cit116","first-page":"553","article-title":"The ROCKET AF study","volume":"13","author":"Capucci","year":"2012","journal-title":"Giornale Italiano di Cardiologia"},{"issue":"1","key":"10.1002\/14651858.CD011373.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.116.021890","article-title":"On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF.[Erratum appears in Circulation. 2016 Aug 23;134(8):e114; PMID: 27550973]","volume":"134","author":"Fordyce","year":"2016","journal-title":"Circulation"},{"issue":"205 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1261-694X(12)70011-1","article-title":"ROCKET-AF: data on rivaroxaban in patients with moderate renal function impairment [abstract]","volume":"18","author":"Fox","year":"2012","journal-title":"Archives des Maladies du Coeur et des Vaisseaux - Pratique"},{"issue":"19","key":"10.1002\/14651858.CD011373.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"European Heart Journal"},{"issue":"8","key":"10.1002\/14651858.CD011373.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/jcph.288","article-title":"Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF","volume":"54","author":"Girgis","year":"2014","journal-title":"Journal of Clinical Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD011373.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacc.2013.11.013","article-title":"Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)","volume":"63","author":"Goodman","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"21 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0122|cit122","article-title":"Predictors of major bleeding risk: Insights from the rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (Rocket AF) [abstract no: 16903]","volume":"124","author":"Goodman","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD011373.pub2-BIB0123|cit123","first-page":"16","article-title":"Rivaroxaban in non valvular atrial fibrillation: subgroups analysis","volume":"82","author":"Greco","year":"2014","journal-title":"Monaldi Archives for Chest Disease"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0124|cit124","first-page":"17","article-title":"Rivaroxaban versus warfarin in patients with AF and prior cerebrovascular disease: Results from the ROCKET-AF trial [abstract]","volume":"31","author":"Hacke","year":"2011","journal-title":"Cerebrovascular Diseases"},{"issue":"21 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0125|cit125","article-title":"Rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: A subgroup analysis of the ROCKET AF trial [abstract no: 15544]","volume":"126","author":"Halperin","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD011373.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","article-title":"Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)","volume":"130","author":"Halperin","year":"2014","journal-title":"Circulation"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0127|cit127","article-title":"Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the ROCKET AF trial [abstract no: 148]","volume":"43","author":"Halperin","year":"2012","journal-title":"Stroke"},{"issue":"4","key":"10.1002\/14651858.CD011373.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","article-title":"Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF","volume":"11","author":"Hankey","year":"2012","journal-title":"Lancet Neurology"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0129|cit129","article-title":"Predictors of intracranial hemorrhage among anticoagulated patients with atrial fibrillation: Insights from the rivaroxaban once-daily oral direct factor XA inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF) [abstract no: 152]","volume":"43","author":"Hankey","year":"2012","journal-title":"Stroke"},{"issue":"12 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"A418","DOI":"10.1016\/S0735-1097(14)60418-6","article-title":"Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the \"Real-world\" michigan anticoagulation quality improvement initiative (MAQI2) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trials [abstract]","volume":"63","author":"Hughey","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD011373.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/eurheartj\/eht492","article-title":"Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF","volume":"35","author":"Jones","year":"2014","journal-title":"European Heart Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/eurheartj\/eht310.4385","article-title":"Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular-atrial fibrillation: insights from ROCKET AF [abstract]","volume":"34","author":"Jones","year":"2013","journal-title":"European Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD011373.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jacc.2012.08.1028","article-title":"Lack of stroke subtype information may hinder indirect comparison between the ROCKET-AF and other trials of new oral anticoagulants","volume":"61","author":"Li","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0134|cit134","first-page":"968","article-title":"Inadequate anticoagulant therapy during end of study transition to open-label vitamin K antagonist therapy: experience in ROCKET AF [abstract no: 5291]","volume":"33","author":"Mahaffey","year":"2012","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD011373.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCOUTCOMES.113.000132","article-title":"End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience","volume":"6","author":"Mahaffey","year":"2013","journal-title":"Circulation. Cardiovascular Quality & Outcomes"},{"issue":"4","key":"10.1002\/14651858.CD011373.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/eurheartj\/eht428","article-title":"Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial","volume":"35","author":"Mahaffey","year":"2014","journal-title":"European Heart Journal"},{"issue":"21 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0137|cit137","article-title":"Ischemic cardiac outcomes in patients with AF treated with vitamin K antagonism or factor Xa inhibition: Results from the ROCKET AF Trial [abstract no: 13482]","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"issue":"12","key":"10.1002\/14651858.CD011373.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"861","DOI":"10.7326\/0003-4819-158-12-201306180-00003","article-title":"Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.[Summary for patients in Ann Intern Med. 2013 Jun 18;158(12):I-28; PMID: 23778921]","volume":"158","author":"Mahaffey","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011373.pub2-BIB0139|cit139","first-page":"18","article-title":"Presentation of the ROCKET AF study on the occasion of the Annual Congress of the American Heart Association. November 15, 2010, Chicago [abstract]","volume":"7","author":"Minar","year":"2010","journal-title":"Zeitschrift fur Gefassmedizin"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"84A","DOI":"10.1378\/chest.1388403","article-title":"Incidence and outcomes of gastrointestinal hemorrhage in patients with atrial fibrillation treated with rivaroxaban or warfarin: Results from the ROCKET AF trial [abstract]","volume":"142","author":"Nessel","year":"2012","journal-title":"Chest"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0141|cit141","first-page":"705","article-title":"Rationale and design of the ROCKET AF study: Comparison of rivaroxaban with warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation [abstract]","volume":"30","author":"Patel","year":"2009","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD011373.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jacc.2012.09.057","article-title":"Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)","volume":"61","author":"Patel","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD011373.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"22 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0144|cit144","article-title":"Management of major bleeding events in patients treated with rivaroxaban versus warfarin: Results from the ROCKET AF trial [abstract]","volume":"128","author":"Piccini","year":"2013","journal-title":"Circulation"},{"issue":"28","key":"10.1002\/14651858.CD011373.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/eurheartj\/ehu083","article-title":"Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial","volume":"35","author":"Piccini","year":"2014","journal-title":"European Heart Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0146|cit146","first-page":"968","article-title":"Relationship between center time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial [abstract no: 5293]","volume":"33","author":"Piccini","year":"2012","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD011373.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"e000521","DOI":"10.1161\/JAHA.113.000521","article-title":"Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial","volume":"3","author":"Piccini","year":"2014","journal-title":"Journal of the American Heart Association"},{"issue":"21 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0148|cit148","article-title":"Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial [abstract no: 19281]","volume":"126","author":"Piccini","year":"2012","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0149|cit149","first-page":"56","article-title":"Independent predictors of mortality in patients with non-valvular atrial fibrillation: results from ROCKET AF [abstract]","volume":"33","author":"Piccini","year":"2012","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD011373.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.112.107128","article-title":"Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF","volume":"127","author":"Piccini","year":"2013","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD011373.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1161\/CIRCULATIONAHA.113.004013","article-title":"Response to letter regarding article, \"renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts\"","volume":"128","author":"Piccini","year":"2013","journal-title":"Circulation"},{"issue":"19","key":"10.1002\/14651858.CD011373.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2013.02.025","article-title":"Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial","volume":"61","author":"Piccini","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"21 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0153|cit153","article-title":"Renal dysfunction is a potent predictor of stroke and systemic embolism among individuals with atrial fibrillation: results from the Rocket AF trial [abstract no: 17137]","volume":"124","author":"Piccini","year":"2011","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD011373.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"e002197","DOI":"10.1161\/JAHA.115.002197","article-title":"Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF","volume":"4","author":"Pokorney","year":"2016","journal-title":"Journal of the American Heart Association"},{"issue":"3","key":"10.1002\/14651858.CD011373.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ahj.2009.11.025","article-title":"Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study","volume":"159","author":"ROCKET AF Study Investigators","year":"2010","journal-title":"American Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD011373.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"A362","DOI":"10.1016\/j.jval.2012.08.945","article-title":"Comparative efficacy and safety analysis of atrial fibrillaion patients treated with dabigatran in RE-LY study (Chads 2 score of 3 or greater) versus rivaroxaban in ROCKET-AF [abstract]","volume":"15","author":"Rasty","year":"2012","journal-title":"Value in Health"},{"issue":"18","key":"10.1002\/14651858.CD011373.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1161\/CIRCULATIONAHA.113.005754","article-title":"Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)","volume":"129","author":"Sherwood","year":"2014","journal-title":"Circulation"},{"issue":"12 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"A1724","DOI":"10.1016\/S0735-1097(14)61727-7","article-title":"The use of dual antiplatelet therapy and patient outcomes in those undergoing PCI in the ROCKET AF trial [abstract]","volume":"63","author":"Sherwood","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"21","key":"10.1002\/14651858.CD011373.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.jacc.2015.09.024","article-title":"Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial","volume":"66","author":"Sherwood","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"issue":"21 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0160|cit160","article-title":"Individual and regional determinants of time in therapeutic range among patients randomized to warfarin in the ROCKET AF trial of rivaroxaban [abstract no: 16169]","volume":"124","author":"Singer","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD011373.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"e000067","DOI":"10.1161\/JAHA.112.000067","article-title":"Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial","volume":"2","author":"Singer","year":"2013","journal-title":"Journal of the American Heart Association"},{"issue":"6","key":"10.1002\/14651858.CD011373.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40256-015-0127-2","article-title":"Rivaroxaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: clinical implications of the ROCKET AF Trial and its subanalyses","volume":"15","author":"Spencer","year":"2015","journal-title":"American Journal of Cardiovascular Drugs"},{"issue":"12 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"A327","DOI":"10.1016\/S0735-1097(14)60327-2","article-title":"Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial [abstract]","volume":"63","author":"Steinberg","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD011373.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.hrthm.2014.03.006","article-title":"Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial","volume":"11","author":"Steinberg","year":"2014","journal-title":"Heart Rhythm"},{"issue":"5","key":"10.1002\/14651858.CD011373.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/eurheartj\/ehu359","article-title":"Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial","volume":"36","author":"Steinberg","year":"2015","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0166|cit166","first-page":"866","article-title":"Higher risk of death and stroke in patients with persistent versus paroxysmal atrial fibrillation: results from the ROCKET AF trial [abstract]","volume":"35","author":"Steinberg","year":"2014","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD011373.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00059-011-3433-8","article-title":"ROCKET AF","volume":"36","author":"Tiefenbacher","year":"2011","journal-title":"Herz"},{"issue":"1","key":"10.1002\/14651858.CD011373.pub2-BIB0168|cit168","first-page":"3","article-title":"Critical issues in megatrials on new oral anticoagulants. Rocket AF: Applying results to low risk patients","volume":"80","author":"Uguccioni","year":"2013","journal-title":"Monaldi Archives for Chest Disease"},{"issue":"21 Suppl 1","key":"10.1002\/14651858.CD011373.pub2-BIB0169|cit169","article-title":"Rivaroxaban is associated with a reduced risk of thromboembolic events and hemorrhagic stroke in patient with heart failure: insights from ROCKET AF [abstract no: 14365]","volume":"126","author":"Diepen","year":"2012","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0170|cit170","first-page":"867","article-title":"Digoxin use in patients with atrial fibrillation is associated with adverse cardiac outcomes: results from the ROCKET AF trial [abstract]","volume":"35","author":"Washam","year":"2014","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD011373.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1161\/STROKEAHA.113.002968","article-title":"Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial","volume":"45","author":"Wong","year":"2014","journal-title":"Stroke"},{"issue":"4","key":"10.1002\/14651858.CD011373.pub2-BIB0172|cit172","first-page":"740","article-title":"Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF","volume":"6","author":"Diepen","year":"2013","journal-title":"Circulation: Heart Failure"},{"issue":"2","key":"10.1002\/14651858.CD011373.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ckj\/sfv146","article-title":"The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials","volume":"9","author":"Caluwe","year":"2016","journal-title":"Clinical Kidney Journal"},{"issue":"8","key":"10.1002\/14651858.CD011373.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003088-200342080-00003","article-title":"Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran","volume":"42","author":"Eriksson","year":"2003","journal-title":"Clinical Pharmacokinetics"},{"issue":"7","key":"10.1002\/14651858.CD011373.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1253\/circj.CJ-14-0942","article-title":"Short-term safety and plasma concentrations of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal impairment","volume":"79","author":"Koretsune","year":"2015","journal-title":"Circulation Journal"},{"issue":"6","key":"10.1002\/14651858.CD011373.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/j.1523-1755.2004.66022.x","article-title":"A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease","volume":"66","author":"Murray","year":"2004","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijcard.2015.04.037","article-title":"Rationale and design of the efficacy of rivaroxaban on renal function in patients with non-valvular atrial fibrillation and chronic kidney disease: the X-NOAC study","volume":"188","author":"Suzuki","year":"2015","journal-title":"International Journal of Cardiology"},{"issue":"25","key":"10.1002\/14651858.CD011373.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.111.020982","article-title":"Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study","volume":"123","author":"Alonso","year":"2011","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD011373.pub2-BIB0179|cit179","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008980.pub2","article-title":"Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation","author":"Bruins Slot","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011373.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1378\/chest.15-1719","article-title":"Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies","volume":"149","author":"Dahal","year":"2016","journal-title":"Chest"},{"issue":"10","key":"10.1002\/14651858.CD011373.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/europace\/euq350","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).[Erratum appears in Europace. 2011 Jul;13(7):1058 Note: Dosage error in article text]","volume":"12","author":"Camm","year":"2010","journal-title":"Europace"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0182|cit182","unstructured":"European Medicines Agency Product-information requirements. 2014 www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/general\/general_content_000199.jsp"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1146\/annurev-med-062209-095159","article-title":"Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism","volume":"62","author":"Eriksson","year":"2011","journal-title":"Annual Review of Medicine"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0184|cit184","unstructured":"US Food Drug Administration 2014 Safety alerts for Muman medical products www.wayback.archive-it.org\/7993\/20170111132857\/http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm380008.htm"},{"issue":"22","key":"10.1002\/14651858.CD011373.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"issue":"18","key":"10.1002\/14651858.CD011373.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD011373.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1161\/CIRCULATIONAHA.108.816082","article-title":"Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study","volume":"119","author":"Go","year":"2009","journal-title":"Circulation"},{"issue":"7650","key":"10.1002\/14651858.CD011373.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD011373.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0190|cit190","unstructured":"Health Canada First Nations and Inuit Health www.canada.ca\/en\/health-canada\/services\/first-nations-inuit-health.html"},{"issue":"7414","key":"10.1002\/14651858.CD011373.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0192|cit192","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD011373.pub2-BIB0193|cit193","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"National Kidney Foundation","year":"2013","journal-title":"Kidney International - Supplement"},{"issue":"13","key":"10.1002\/14651858.CD011373.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.jacc.2016.06.057","article-title":"Atrial fibrillation and thromboembolism in patients with chronic kidney disease","volume":"68","author":"Lau","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD011373.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.[Erratum appears in Ann Intern Med. 2008 Oct 7;149(7):519]","volume":"145","author":"Levey","year":"2006","journal-title":"Annals of Internal Medicine"},{"issue":"9","key":"10.1002\/14651858.CD011373.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.[Erratum appears in Ann Intern Med. 2011 Sep 20;155(6):408]","volume":"150","author":"Levey","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"50","key":"10.1002\/14651858.CD011373.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"e2233","DOI":"10.1097\/MD.0000000000002233","article-title":"Effectiveness and safety of warfarin in dialysis patients with atrial fibrillation: a meta-analysis of observational studies","volume":"94","author":"Liu","year":"2015","journal-title":"Medicine"},{"issue":"12","key":"10.1002\/14651858.CD011373.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2010.12.013","article-title":"Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk","volume":"57","author":"Marinigh","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD011373.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/ndt\/gfv009","article-title":"Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis","volume":"30","author":"Masson","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD011373.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.amjcard.2012.03.049","article-title":"Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation","volume":"110","author":"Miller","year":"2012","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD011373.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/1076029613486539","article-title":"The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis","volume":"19","author":"Mitchell","year":"2013","journal-title":"Clinical & Applied Thrombosis\/Hemostasis"},{"issue":"4","key":"10.1002\/14651858.CD011373.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"e002097","DOI":"10.1161\/JAHA.112.002097","article-title":"Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in Medicare patients","volume":"1","author":"Nelson","year":"2012","journal-title":"Journal of the American Heart Association"},{"issue":"3","key":"10.1002\/14651858.CD011373.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1053\/j.ajkd.2013.02.381","article-title":"Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation","volume":"62","author":"Ng","year":"2013","journal-title":"American Journal of Kidney Diseases"},{"issue":"7","key":"10.1002\/14651858.CD011373.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease.[Erratum appears in N Engl J Med. 2012 Dec 6;367(23):2262]","volume":"367","author":"Olesen","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD011373.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1161\/STROKEAHA.113.001701","article-title":"Preventing stroke in patients with chronic kidney disease and atrial fibrillation: benefit and risks of old and new oral anticoagulants","volume":"44","author":"Reinecke","year":"2013","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0206|cit206","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD011373.pub2-BIB0207|cit207","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"6","key":"10.1002\/14651858.CD011373.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ahj.2010.03.027","article-title":"Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC).[Erratum appears in Am Heart J. 2010 Dec;160(6):1190], [Erratum appears in Am Heart J. 2011 Oct;162(4):794]","volume":"159","author":"Soliman","year":"2010","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD011373.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","article-title":"Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects","volume":"47","author":"Stangier","year":"2008","journal-title":"Clinical Pharmacokinetics"},{"issue":"5","key":"10.1002\/14651858.CD011373.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/heart.86.5.516","article-title":"Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew\/Paisley study","volume":"86","author":"Stewart","year":"2001","journal-title":"Heart"},{"issue":"9658","key":"10.1002\/14651858.CD011373.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(09)60040-4","article-title":"Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited","volume":"373","author":"Watson","year":"2009","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD011373.pub2-BIB0212|cit212","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011373","article-title":"New oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease","author":"Kimachi","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011373.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T04:33:48Z","timestamp":1697085228000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011373.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,11,6]]},"references-count":212,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011373.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,6]]}}}